RevaTis
RevaTis was launched in 2013 by serial entrepreneur Didier SERTYEN, Professor at the University of Liège, to develop a global therapeutic concept in veterinary regenerative medicine. This innovative approach is centered around a patented technology to isolate pluripotent adult mesenchymal stem cells from muscular micro-biopsies, combined with advanced biobanking services for cell sourcing and aseptic isolator units for cell amplification. Although performance horses are the primary target of this integrated therapeutical strategy, RevaTis has bold plans to transfer its unique muscle-derived stem cell treatment to human applications. A joint-venture with an Indian company has been recently announced regarding the organization of human clinical trials for osteoarthritis using RevaTis technology.
This Indian alliance is a timely addition to an already large network of subsidiaries that RevaTis is creating around the world, namely in Texas, Dubai and Hong Kong, to serve multiple equine markets in demand of novel therapeutic approaches. It is back in 2011 that a collaboration agreement was signed between WBC and RevaTis with the aim of helping the then-nascent spin-off develop and commercialize its veterinarian products and services. WBC also contributed to secure an additional 90 k€ investment to accelerate the finalization of its cell manufacturing system.